Distinguished in Rheumatoid Arthritis (RA)

Dr. Jeffrey L. Kaine

Rheumatology
1945 Versailles St, 2nd Floor, 
Sarasota, FL 
Distinguished in Rheumatoid Arthritis (RA)
1945 Versailles St, 2nd Floor, 
Sarasota, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Kaine is a Rheumatologist in Sarasota, Florida. Dr. Kaine is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Axial Spondyloarthritis (AxSpA), and Ankylosing Spondylitis.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles and participated in 4 clinical trials in the study of Rheumatoid Arthritis (RA).

Specialties
Rheumatology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1945 Versailles St, 2nd Floor, Sarasota, FL 34239

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug, Biological
Study Drug: Zostavax Herpes Zoster Vaccine
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

13 Total Publications

Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States.
Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States.
Journal: ACR open rheumatology
Published: August 26, 2022
Similar Doctors
Distinguished in Rheumatoid Arthritis (RA)
Dr. Yoel Drucker
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Yoel Drucker
Rheumatology

Weitzner Yonker And Kaine MD PA

1945 Versailles St, Fl 2, 
Sarasota, FL 
 (0.1 miles away)
941-365-0770
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Yoel Drucker is a Rheumatologist in Sarasota, Florida. Dr. Drucker is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, Osteoporosis, and Psoriatic Arthritis. Dr. Drucker is currently accepting new patients.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Leslie Tar
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Leslie Tar
Rheumatology

Allergy & Arthritis Treatment Centers LLC

22226 Westchester Blvd, 
Port Charlotte, FL 
 (35.8 miles away)
914-244-8612
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leslie Tar is a Rheumatologist in Port Charlotte, Florida. Dr. Tar is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Fibromyalgia, Hives, and Common Variable Immune Deficiency.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Sash S. Seshadri
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Sash S. Seshadri
Rheumatology
2841 Tamiami Trl, 
Port Charlotte, FL 
 (33.8 miles away)
941-627-5151
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sash Seshadri is a Rheumatologist in Port Charlotte, Florida. Dr. Seshadri is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Sjogren Syndrome. Dr. Seshadri is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaine's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile